Entrada Therapeutics, Inc. (TRDA) Misses Q3 EPS by 7c
Tweet
Share
E-mailGet Alerts TRDA Hot Sheet
Join SI Premium – FREE
Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q3 EPS of ($1.06), $0.07 worse than the analyst estimate of ($0.99). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $7.03 million.
For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jack Henry (JKHY) Tops Q4 EPS by 13c
- JPMorgan Downgrades Mereo BipPharma Group (MREO) to Underweight
- Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
